ALXO — ALX Oncology Holdings Cashflow Statement
0.000.00%
Last trade - 00:00
- $653.48m
- $482.68m
- 44
- 14
- 87
- 46
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -19.2 | -45.7 | -83.5 | -123 | -161 |
Depreciation | |||||
Non-Cash Items | 0.308 | 7 | 19.3 | 24.1 | 21.3 |
Unusual Items | |||||
Purchased R&D | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 4.26 | 0.247 | -4.03 | 9.85 | 8.3 |
Change in Accounts Receivable | |||||
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Other Liabilities | |||||
Cash from Operating Activities | -14.2 | -38.3 | -68.1 | -89.2 | -130 |
Capital Expenditures | -0.353 | -0.031 | -4.92 | -1.43 | -1.27 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | — | 0.641 | — | -234 | 45.9 |
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Cash from Investing Activities | -0.353 | 0.61 | -4.92 | -235 | 44.7 |
Financing Cash Flow Items | — | -10.4 | — | -0.655 | 58.9 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 15.4 | 463 | 2.47 | 9.86 | 59.3 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 0.755 | 425 | -70.6 | -315 | -26.4 |